RxDoctor Payments DataLook up a doctor →

Jeffrey Frank, MD

Neurology · Louisville, KYNPI 1073664470

Payments from drug & device makers

$181,002in general payments, 2019–2025

Across 962 payments — averaging $188.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$42K
  • Amgen$36K
  • Biohaven Pharmaceuticals, Inc.$32K
  • AbbVie$31K
  • Teva Pharmaceuticals USA, Inc.$20K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • plus $12K from 29 others

What the payments were for

  • Consulting fees$22,18812%
  • Speaking & faculty fees$138,00576%
  • Travel & lodging$3,7922%
  • Food & beverage$17,0179%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$181,002 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$30,814
Medicare patients
171
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe202$187,708
UbrelvyUbrogepant144$184,540
QuliptaAtogepant142$173,605
Nurtec OdtRimegepant Sulfate119$153,943
Emgality PenGalcanezumab-Gnlm95$82,511
KeppraLevetiracetam23$39,311
Ajovy AutoinjectorFremanezumab-Vfrm28$27,164
TopamaxTopiramate15$18,495
Zonisamide231$7,734
Carbamazepine ErCarbamazepine36$7,135
FetzimaLevomilnacipran Hcl12$6,087
ZonisadeZonisamide11$5,245
Oxcarbazepine66$4,884
Gabapentin285$4,856
Duloxetine Hcl233$4,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Fetzima$31,181$364,232298 claims
PfizerNurtec Odt, Dilantin$977$157,715136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →